BRPI0412190A - sólidos com camada de difusão modulada - Google Patents

sólidos com camada de difusão modulada

Info

Publication number
BRPI0412190A
BRPI0412190A BRPI0412190-2A BRPI0412190A BRPI0412190A BR PI0412190 A BRPI0412190 A BR PI0412190A BR PI0412190 A BRPI0412190 A BR PI0412190A BR PI0412190 A BRPI0412190 A BR PI0412190A
Authority
BR
Brazil
Prior art keywords
diffusion layer
modulated
solids
drug
poorly soluble
Prior art date
Application number
BRPI0412190-2A
Other languages
English (en)
Inventor
Michael Hawley
Walter Morozowich
Michael S Bergren
John W Skoug
Philip R Nixon
John M Heimlich
Ping Gao
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0412190A publication Critical patent/BRPI0412190A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Abstract

"SóLIDOS COM CAMADA DE DIFUSãO MODULADA". A presente invenção refere-se aos sólidos modulados pela cadeia de difusão, que incluam um excipiente e um sal solúvel de um fármaco básico e pouco solúvel; um sal solúvel de um fármaco ácido pouco solúvel; ou um fármaco não-ionizável e pouco solúvel, são úteis, por exemplo, para a melhoria da veiculação de fármacos.
BRPI0412190-2A 2003-07-01 2004-06-29 sólidos com camada de difusão modulada BRPI0412190A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48420503P 2003-07-01 2003-07-01
PCT/US2004/021143 WO2005004763A1 (en) 2003-07-01 2004-06-29 Diffusion layer modulated solids

Publications (1)

Publication Number Publication Date
BRPI0412190A true BRPI0412190A (pt) 2006-08-22

Family

ID=34062033

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412190-2A BRPI0412190A (pt) 2003-07-01 2004-06-29 sólidos com camada de difusão modulada

Country Status (9)

Country Link
US (1) US20050042291A1 (pt)
EP (1) EP1643948A1 (pt)
JP (1) JP2007527394A (pt)
AR (1) AR044983A1 (pt)
BR (1) BRPI0412190A (pt)
CA (1) CA2531116A1 (pt)
MX (1) MXPA06000178A (pt)
TW (1) TW200514576A (pt)
WO (1) WO2005004763A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
WO2011127244A2 (en) * 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
DE102011113749A1 (de) * 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
CA2852618C (en) 2011-10-18 2019-06-18 Raqualia Pharma Inc. Pharmaceutical composition
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4028772A (en) * 1971-04-02 1973-09-27 Merck & Co., Inc Chemical processes
US4355091A (en) * 1980-08-25 1982-10-19 Polaroid Corporation Polymeric neutralizing layer with temporary crosslinks from an organo-metallic crosslinking agent
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
CA2328703C (en) * 1998-06-11 2007-10-30 Pharmacia & Upjohn Company Delavirdine tablet formulation
ATE307808T1 (de) * 1999-03-24 2005-11-15 Scherer Technologies Inc R P Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
JP2003518485A (ja) * 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren

Also Published As

Publication number Publication date
EP1643948A1 (en) 2006-04-12
JP2007527394A (ja) 2007-09-27
US20050042291A1 (en) 2005-02-24
WO2005004763A1 (en) 2005-01-20
TW200514576A (en) 2005-05-01
MXPA06000178A (es) 2006-04-11
AR044983A1 (es) 2005-10-12
CA2531116A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
BRPI0600777A (pt) método e sistema para a criação, armazenamento, gerenciamento e consumo de dados especìficos de cultura
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
BRPI0516577A (pt) agentes terapêuticos com toxicidade diminuìda
DE60007095D1 (de) Calanolide zur hemmung von btk
BRPI0508744A (pt) sistema de retenção gástrica e processo para revestir um comprimido ou cápsula
WO2007113648A3 (en) Ctla4 antibody combination therapy
BRPI0415409A (pt) uso de efetuadores de ciclases de glutaminila e glutamato
BR0112104A (pt) Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
CY1113679T1 (el) Απταμερες εναντι midkine και χρηση αυτου
BRPI0702965A (pt) parte de sistema de implante dental
BR0308613A (pt) Combinação de compostos orgânicos
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
ECSP024341A (es) Composiciones farmaceuticas
ATE485261T1 (de) Salicylsäurederivate
CY1113824T1 (el) Ενδορινικες συνθεσεις
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
MA29481B1 (fr) Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase
BRPI0412190A (pt) sólidos com camada de difusão modulada
NO20054631L (no) Antistoff mot tumorspesifikt antigen som mal
WO2008078109A3 (en) Medicament
MY140530A (en) Antineoplasic compounds and pharmaceuticals compositions thereof
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
BR0314838A (pt) Sistema de liberação controlada, e, processo para preparar comprimidos de liberação controlada de temozolomida
DE602006011053D1 (de) Verbindungen zur inhibierung von apoptose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.